Rosetta's miR-451 could enhance Gleevec in brain tumours
This article was originally published in Clinica
One of Rosetta Genomics' microRNAs, miR-451, has been shown in vitro to inhibit cell growth of glioblastoma, the most common and aggressive form of primary brain tumour. When combined with Novartis's anticancer drug Gleevec (imatinib mesilate, also known as Glivec), a synergistic effect inhibiting glioblastoma cell proliferation was seen. Gleevec is a tyrosine kinase inhibitor that is used in certain leukaemias and gastrointestinal stromal tumours, as well as brain tumours. The study will be published in the November issue of Biochemical and Biophysical Research Communications.